{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:03:19Z","timestamp":1770508999192,"version":"3.49.0"},"reference-count":63,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2015,12,2]]},"DOI":"10.1517\/14740338.2015.1108962","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T13:13:23Z","timestamp":1446470003000},"page":"1969-1978","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis"],"prefix":"10.1517","volume":"14","author":[{"given":"Brian","family":"Berman","sequence":"first","affiliation":[{"name":"Center for Clinical and Cosmetic Research, Aventura, FL, USA"},{"name":"Center for Clinical and Cosmetic Research, 2925 Aventura Boulevard, Suite 205, Aventura, FL 33180, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,11,2]]},"reference":[{"key":"e_1_3_1_2_1","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers."},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S28905"},{"key":"e_1_3_2_2_1","first-page":"184","article-title":"Cost for the treatment of actinic keratosis on the rise in Australia","volume":"3","author":"Perera E","year":"2014","unstructured":"Perera E, McGuigan S, Sinclair R. Cost for the treatment of actinic keratosis on the rise in Australia. F1000Res. 2014;3:184.","journal-title":"F1000Res"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.134"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13132"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","first-page":"22368","DOI":"10.5070\/D3204022368","article-title":"Top dermatologic diagnoses by age","volume":"20","author":"Landis ET","year":"2014","unstructured":"Landis ET, Davis SA, Taheri A, et al. Top dermatologic diagnoses by age. Dermatol Online J. 2014;20:22368.","journal-title":"Dermatol Online J"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12702"},{"key":"e_1_3_2_9_1","first-page":"CD004415","article-title":"Interventions for actinic keratoses","volume":"12","author":"Gupta AK","year":"2012","unstructured":"Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_10_1","unstructured":"LEO Pharma. Picato\u00ae (ingenol mebutate) gel 0.015% 0.05% [Internet]. Prescribing information; [cited 2015 Aug 10]. Available from: http:\/\/www.picato.com\/_pdf\/PrescribingInformation.pdf"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2012.12050"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.050"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1684\/ejd.2014.2368","article-title":"The European medicines agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the committee for medicinal products for human use (CHMP)","volume":"24","author":"Tzogani K","year":"2014","unstructured":"Tzogani K, Nagercoil N, Hemmings RJ, et al. The European medicines agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the committee for medicinal products for human use (CHMP). Eur J Dermatol. 2014;24:457\u2013463.","journal-title":"Eur J Dermatol"},{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.008"},{"key":"e_1_3_3_3_1","first-page":"19","article-title":"Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100\u00a0cm2 on the forearm(s) of patients with actinic keratosis","volume":"7","author":"Anderson L","year":"2014","unstructured":"Anderson L, Jarrett M, Schmieder G, et al. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100\u00a0cm2 on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol. 2014;7:19\u201329.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_2_1","first-page":"154","article-title":"Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results","volume":"13","author":"Berman B","year":"2014","unstructured":"Berman B, Goldenberg G, Hanke W, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol. 2014;13:154\u2013160.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_3_1","first-page":"1353","article-title":"Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT","volume":"13","author":"Berman B","year":"2014","unstructured":"Berman B, Nestor MS, Newburger J, et al. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. J Drugs Dermatol. 2014;13:1353\u20131356.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_4_1","first-page":"269","article-title":"Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice","volume":"13","author":"Bettencourt MS","year":"2014","unstructured":"Bettencourt MS. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. J Drugs Dermatol. 2014;13:269\u2013273.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_5_1","first-page":"35","article-title":"Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers","volume":"7","author":"Dosik JS","year":"2014","unstructured":"Dosik JS, Damstra M, Udell C, et al. Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol. 2014;7:35\u201342.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"e_1_3_4_6_1","first-page":"AB191","article-title":"Safety of follow-up field application of ingenol mebutate 0.015% gel for actinic keratoses on face and scalp","volume":"72","author":"Garbe C","year":"2015","unstructured":"Garbe C, Basset-Seguin N, Poulin Y, et al. Safety of follow-up field application of ingenol mebutate 0.015% gel for actinic keratoses on face and scalp. J Am Acad Dermatol. 2015;72(Suppl 1):AB191.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S70970"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111170"},{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13211"},{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13063"},{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2008.00497.x"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.1651.3.12"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2837"},{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.11.8123"},{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3403"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-4117"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0458-9"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.418"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4303"},{"key":"e_1_3_9_8_1","unstructured":"3M Health Care Limited. Aldara (Imiquimod): highlights of prescribing information [Internet]. [cited 2015 Aug 10]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020723s020lbl.pdf"},{"key":"e_1_3_9_9_1","unstructured":"Allergan Inc. Fluoroplex (fluorouracil) 1% topical cream [Internet]. Prescribing information; [cited 2013 Apr 26]. Available from: http:\/\/www.allergan.com\/assets\/pdf\/fluoroplex_pi.pdf"},{"key":"e_1_3_9_10_1","unstructured":"Almirall Ltd. Solaraze. Summary of product characteristics [Internet]. [cited 2015 Aug 10]. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/21229\/SPC"},{"key":"e_1_3_9_11_1","doi-asserted-by":"crossref","unstructured":"Electronic Medicines Consortium (eMC). Solaraze SmPC [Internet]. [cited 2015 July 15]. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/21229\/SPC","DOI":"10.1016\/S1634-7072(15)72177-X"},{"key":"e_1_3_9_12_1","unstructured":"Graceway Pharmaceuticals. Aldara (imiquimod) cream 5%. Prescribing information [Internet]. [cited 2015 July 16]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020723s022lbl.pdf"},{"key":"e_1_3_9_13_1","unstructured":"Pharmaderm. Solaraze gel. Prescribing information [Internet]. [cited 2015 Aug 10]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021005s013lbl.pdf"},{"key":"e_1_3_9_14_1","unstructured":"Food and Drug Administration (FDA). Zyclara (imiquimod) cream 3.75%. Prescribing information Graceway Pharmaceuticals [Internet]. [cited 2015 July 27]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/201153s000 022483s001lbl.pdf"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0059-9"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2766"},{"key":"e_1_3_9_17_1","first-page":"741","article-title":"Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results","volume":"13","author":"Berman B","year":"2014","unstructured":"Berman B, Goldenberg G, Hanke CW, et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol. 2014;13:741\u2013747.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_9_18_1","unstructured":"European Medicines Agency. Picato: EPAR\u2014public assessment report; [cited 2015 July 10]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002275\/human_med_001600.jsp&mid=WC0b01ac058001d124."},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0049-y"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2003.00003.x"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.010"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126257"},{"key":"e_1_3_9_23_1","first-page":"227","article-title":"Zyclara (imiquimod) cream, 3.75%","volume":"8","author":"Gupta AK","year":"2010","unstructured":"Gupta AK, Cooper EA, Abramovits W. Zyclara (imiquimod) cream, 3.75%. Skinmed. 2010;8:227\u2013229.","journal-title":"Skinmed"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0070-9"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-329"},{"key":"e_1_3_9_26_1","first-page":"74","article-title":"Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod","volume":"33","author":"Mashiah J","year":"2008","unstructured":"Mashiah J, Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol. 2008;33:74\u201376.","journal-title":"Clin Exp Dermatol"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20143058"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221312798889301"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.045"},{"key":"e_1_3_9_30_1","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson MR","year":"1999","unstructured":"Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006\u20132011.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04432.x"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12434"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03029.x"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04386.x"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.01.036"},{"key":"e_1_3_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12840"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14740338.2015.1108962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:32:16Z","timestamp":1770417136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14740338.2015.1108962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,2]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12,2]]}},"alternative-id":["10.1517\/14740338.2015.1108962"],"URL":"https:\/\/doi.org\/10.1517\/14740338.2015.1108962","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}